(Q24201292)

5

0 references

Yulia Lin

2

object named as

Yulia Lin

0 references

Janet Birchall

4

object named as

Janet Birchall

0 references

Chris Hyde

6

object named as

Chris Hyde

0 references

author name string

Ewurabena Simpson

Cochrane Database of Systematic Reviews

1

0 references

language of work or name

English

0 references

publication date

14 March 2012

0 references

published in

0 references

issue

3

0 references

page(s)

CD005011

0 references

cites work

Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant activated factor VII in cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting--results of a single centre pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Hemostasis in liver resection surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant activated factor VII for acute intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Haemopoietic stem cell transplants: the impact of haemorrhagic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Activated recombinant factor VII in orthotopic liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Blood loss in major spine surgery: are there effective measures to decrease massive hemorrhage in major spine fusion surgery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Pharmacotherapy for mechanical circulatory support: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Evidence-based Emergency Medicine/Critically Appraised Topic. The efficacy of recombinant activated factor VII in severe trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Haemostatic drugs for traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

rFVII for pediatric acute intracranial hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant factor VIIa should be used in massive obstetric haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant factor VIIa should be used in massive obstetric haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant factor VIIa for life-threatening post-partum haemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant factor VIIa in preterm neonates with prolonged prothrombin time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Potential role for rFVIIa in transfusion medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Evidence and desperation in off-label prescribing: recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

The use of recombinant factor VIIa in the treatment of bleeding disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Haemostatic drug therapies for acute primary intracerebral haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Recombinant activated factor VII in chronic liver diseases: Should we be afraid of thromboembolic events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Safety of recombinant activated factor VII in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomiz

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Recombinant FVIIa for intractable hemorrhage: more questions than answers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005011.PUB4

7 January 2021

10.1002/14651858.CD005011.PUB4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22419303

1 reference

Consolidated OpenCitations Corpus – April 2017